{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T18:57:54Z","timestamp":1735585074215},"reference-count":48,"publisher":"Consilium Medicum","issue":"12","license":[{"start":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T00:00:00Z","timestamp":1607990400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Terapevticheskii arkhiv"],"abstract":"<jats:p>Pulmonary arterial hypertension (PAH) is severe and often times rapidly progressive disease with fatal outcome. The concept of initial combination of PAH-specific therapies in high risk patients at baseline was first described in the European guidelines on pulmonary hypertension (PH) in 2009, and in low or intermediate risk patients at baseline in 2015. Interestingly, that in Cologne Experts Consensus, and then in the 6th World Symposium on PH medical community started considering initial combination therapy as one of the most important pillars in PAH treatment algorithms in 2018. As of August 2020, as many as 8 formulations of 7 reference PAH-specific drugs are licensed for medical use in the Russian Federation. On top of that, 6 abbreviated drugs (generics) have also become available few years ago. Unfortunately, intravenous and subcutaneous prostacyclin analogs (PCA) and tadalafil are not approved for PH patients treatment in the Russian Federation. In this narrative review paper we attempted to describe studies on initial dual combination therapy with PAH-specific drugs registered in Russia, i.e. ambrisentan and riociguat, macitentan and riociguat, macitentan and sildenafil in low or intermediate risk patients at baseline, as well as iloprost inhaled and sildenafil, iloprost inhaled and bosentan in high risk patients. Some beneficial pharmacological effects due to the synergy between ambrisentan plus riociguat, and inhaled iloprost plus sildenafil appear to be interesting and require further clinical confirmation. Other initial combinations of PAH-specific agents require large-scale clinical trials as well.<\/jats:p>","DOI":"10.26442\/00403660.2020.12.000840","type":"journal-article","created":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T09:12:59Z","timestamp":1612775579000},"page":"80-85","source":"Crossref","is-referenced-by-count":9,"title":["Advantages and limitations of initial combination therapy in pulmonary arterial hypertension patients in Russia"],"prefix":"10.26442","volume":"92","author":[{"given":"A. A.","family":"Shmalts","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. V.","family":"Gorbachevsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18344","published-online":{"date-parts":[[2020,12,15]]},"reference":[{"key":"ref1","unstructured":"\u041c\u0430\u0440\u0442\u044b\u043d\u044e\u043a \u0422.\u0412. \u041b\u0435\u0433\u043e\u0447\u043d\u0430\u044f \u0433\u0438\u043f\u0435\u0440\u0442\u0435\u043d\u0437\u0438\u044f: \u0434\u0438\u0430\u0433\u043d\u043e\u0441\u0442\u0438\u043a\u0430 \u0438 \u043b\u0435\u0447\u0435\u043d\u0438\u0435. \u041c.: \u041c\u0435\u0434\u0438\u0446\u0438\u043d\u0441\u043a\u043e\u0435 \u0438\u043d\u0444\u043e\u0440\u043c\u0430\u0446\u0438\u043e\u043d\u043d\u043e\u0435 \u0430\u0433\u0435\u043d\u0442\u0441\u0442\u0432\u043e, 2018 [Martynyuk TV. Pulmonary hypertension: diagnosis and treatment. Moscow: Medicinskoe informacionnoe agentstvo, 2018 (In Russ.)]."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-115-5-343"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Gali\u00e9 N, Palazzini M, Manes A. Pulmonary arterial hypertension: From the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur Heart J. 2010;31:2080-6.","DOI":"10.1093\/eurheartj\/ehq152"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv317"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2018.11.030"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"\u0428\u043c\u0430\u043b\u044c\u0446 \u0410.\u0410., \u0413\u043e\u0440\u0431\u0430\u0447\u0435\u0432\u0441\u043a\u0438\u0439 \u0421.\u0412. \u0421\u0438\u0441\u0442\u0435\u043c\u0430\u0442\u0438\u0447\u0435\u0441\u043a\u0438\u0439 \u043e\u0431\u0437\u043e\u0440 \u043a\u0430\u043a \u043e\u0441\u043d\u043e\u0432\u0430 \u043a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0438\u0445 \u0440\u0435\u043a\u043e\u043c\u0435\u043d\u0434\u0430\u0446\u0438\u0439: \u0440\u0435\u043a\u043e\u043c\u0435\u043d\u0434\u0430\u0446\u0438\u0438 CHEST \u043f\u043e \u0442\u0435\u0440\u0430\u043f\u0438\u0438 \u043b\u0435\u0433\u043e\u0447\u043d\u043e\u0439 \u0430\u0440\u0442\u0435\u0440\u0438\u0430\u043b\u044c\u043d\u043e\u0439 \u0433\u0438\u043f\u0435\u0440\u0442\u0435\u043d\u0437\u0438\u0438 \u0443 \u0432\u0437\u0440\u043e\u0441\u043b\u044b\u0445. \u0422\u0435\u0440\u0430\u043f\u0435\u0432\u0442\u0438\u0447\u0435\u0441\u043a\u0438\u0439 \u0430\u0440\u0445\u0438\u0432. 2019;91(12):105-14 [Shmalts AA, Gorbachevsky SV. A systematic review as \u0430 method of gathering scientific evidence into clinical guidelines: CHEST-2019 guideline for the therapy pulmonary arterial hypertension in adults. Therapeutic Archive. 2019; 91(12): 105-14 (In Russ.)].","DOI":"10.26442\/00403660.2019.12.000468"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ehj.2004.09.014"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehp297"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.10.031"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2018.08.082"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01889-2018"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.24411\/2076-4766-2020-10002"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1413687"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00116313"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.04.00028404"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2011.11.002"},{"key":"ref17","unstructured":"\u0413\u043e\u0441\u0443\u0434\u0430\u0440\u0441\u0442\u0432\u0435\u043d\u043d\u044b\u0439 \u0440\u0435\u0435\u0441\u0442\u0440 \u043b\u0435\u043a\u0430\u0440\u0441\u0442\u0432\u0435\u043d\u043d\u044b\u0445 \u0441\u0440\u0435\u0434\u0441\u0442\u0432 [State Register of Medicines (In Russ.)]. https:\/\/grls.rosminzdrav.ru"},{"key":"ref18","unstructured":"\u0413\u043e\u0441\u0443\u0434\u0430\u0440\u0441\u0442\u0432\u0435\u043d\u043d\u044b\u0439 \u0440\u0435\u0435\u0441\u0442\u0440 \u043b\u0435\u043a\u0430\u0440\u0441\u0442\u0432\u0435\u043d\u043d\u044b\u0445 \u0441\u0440\u0435\u0434\u0441\u0442\u0432, 2008 [State Register of Medicines, 2008 (In Russ.)]. https:\/\/grls.rosminzdrav.ru\/ Grls_View_v2.aspx?routingGuid=08c04b68-236a-4548-b0fb-8f8862a635d4&t="},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2018.01.115"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Thornton CS, Helmersen D, Thakrar MV, et al. Early Echocardiographic Improvements with Upfront Riociguat and Ambrisentan Combination Therapy for Incident Pulmonary Arterial Hypertension. J Heart Lung Transplant. 2020;39(4S):S508-509. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1053249820301376","DOI":"10.1016\/j.healun.2020.01.120"},{"key":"ref21","unstructured":"Liang F, Yang S, Fan P, et al., Ambrisentan And Riociguat Synergistically Relax Endothelin-Induced Contraction Of Rat Pulmonary Arteries. Am J Respir Critical Care Med. 2014;189:A3324. https:\/\/www.atsjournals.org\/doi\/pdf\/10.1164\/ajrccm-conference.2014.189.1_MeetingAbstracts.A3324"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02043-2015"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Rinaldi A, Dardi F, Albini A, et al. Haemodynamic and exercise effects of different types of initial oral combination therapy in pulmonary arterial hypertension. Eur Heart J. 2018;39(Suppl. 1):1328. https:\/\/academic.oup.com\/eurheartj\/article\/39\/suppl_1\/ehy566.P6341\/5081319","DOI":"10.1093\/eurheartj\/ehy566.P6341"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02044-2014"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-017-06743"},{"key":"ref26","unstructured":"\u0422\u0440\u0430\u043a\u043b\u0438\u0440\u00ae. \u0418\u043d\u0441\u0442\u0440\u0443\u043a\u0446\u0438\u044f \u043f\u043e \u043f\u0440\u0438\u043c\u0435\u043d\u0435\u043d\u0438\u044e \u043b\u0435\u043a\u0430\u0440\u0441\u0442\u0432\u0435\u043d\u043d\u043e\u0433\u043e \u043f\u0440\u0435\u043f\u0430\u0440\u0430\u0442\u0430 \u0434\u043b\u044f \u043c\u0435\u0434\u0438\u0446\u0438\u043d\u0441\u043a\u043e\u0433\u043e \u043f\u0440\u0438\u043c\u0435\u043d\u0435\u043d\u0438\u044f. \u041b\u0421-002509-27072011 [Tracleer\u00ae. Instructions for the use of a medicinal product for medical use. \u041b\u0421-002509-27072011 (In Russ.)]. http:\/\/grls.rosminzdrav.ru\/ Grls_View_v2.aspx?routingGuid=3ee54c15-dde4-4f9c-ad24-98b60d764792&t=6787405a-d4a4-44db-8d8b-58c25dc6a356"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1177\/0091270008324180"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12382"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1177\/2045894019826944"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Ghofrani HA, Gali\u00e9 N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369(4):330-40.","DOI":"10.1056\/NEJMoa1209655"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369:809-18.","DOI":"10.1056\/NEJMoa1213917"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Noordegraaf AV, Channick R, Cottreel E, et al. Results from the REPAIR Study Final Analysis: Effects of Macitentan on Right Ventricular (RV) Remodelling in Pulmonary Arterial Hypertension (PAH). J Heart Lung Transplant. 2020;39(4S):S16. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1053249820311578","DOI":"10.1016\/j.healun.2020.01.1140"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12447"},{"key":"ref34","unstructured":"\u0412\u0435\u043d\u0442\u0430\u0432\u0438\u0441\u00ae. \u0418\u043d\u0441\u0442\u0440\u0443\u043a\u0446\u0438\u044f \u043f\u043e \u043f\u0440\u0438\u043c\u0435\u043d\u0435\u043d\u0438\u044e \u043b\u0435\u043a\u0430\u0440\u0441\u0442\u0432\u0435\u043d\u043d\u043e\u0433\u043e \u043f\u0440\u0435\u043f\u0430\u0440\u0430\u0442\u0430 \u0434\u043b\u044f \u043c\u0435\u0434\u0438\u0446\u0438\u043d\u0441\u043a\u043e\u0433\u043e \u043f\u0440\u0438\u043c\u0435\u043d\u0435\u043d\u0438\u044f. \u041b\u0421\u0420-005775\/10-160117 [Ventavis\u00ae. Instructions for the use of a medicinal product for medical use. \u041b\u0421\u0420-005775\/10-160117 (In Russ.)]. http:\/\/grls.rosminzdrav.ru\/ Grls_View_v2.aspx?routingGuid=50043553-1cc8-454a-97a3-b88491ce7347&t=768437a4-fa2e4097-a413-4ef4f7bde608"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1161\/hc3601.096826"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-136-7-200204020-00008"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.1995.75.4.725"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.1994.266.5.L536"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4684-6015-5_15"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2013.03.040"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-015-0164-2"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.05280"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1002\/lt.21310"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00007-2017"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.03.031"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2016.03.004"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(16)00027-8"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Chin KM, Sitbon O, Doelberg M, et al. Efficacy and Safety of Initial Triple Oral Versus Initial Double Oral Combination Therapy in Patients with Newly Diagnosed Pulmonary Arterial Hypertension (PAH): Results of the Randomized Controlled TRITON Study. Amn Thorac Soc. 2020:A2928-A2928. https:\/\/www.atsjournals.org\/doi\/10.1164\/ajrccm-conference.2020.201.1_MeetingAbstracts.A2928","DOI":"10.1164\/ajrccm-conference.2020.201.1_MeetingAbstracts.A2928"}],"container-title":["Terapevticheskii arkhiv"],"original-title":[],"link":[{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/60260\/43427","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/60260\/43427","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T20:14:18Z","timestamp":1634156058000},"score":1,"resource":{"primary":{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/view\/60260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,15]]},"references-count":48,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12,15]]}},"URL":"https:\/\/doi.org\/10.26442\/00403660.2020.12.000840","relation":{},"ISSN":["2309-5342","0040-3660"],"issn-type":[{"value":"2309-5342","type":"electronic"},{"value":"0040-3660","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,15]]}}}